Research Reports Coverage on Generic Drugs Stocks -- SCYNEXIS, Supernus Pharma, Lipocine, and Carbylan Therapeutics

Oct 05, 2016, 09:08 ET from Chelmsford Park SA

NEW YORK, October 5, 2016 /PRNewswire/ --

Pre-market, closely evaluates the most recent performances of the following U.S. Generic Drugs equities: SCYNEXIS Inc. (NASDAQ: SCYX), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), Lipocine Inc. (NASDAQ: LPCN), and Carbylan Therapeutics Inc. (NASDAQ: CBYL). According to a report released by ReportsnReports in May 2016, the global generic drugs market is expected to grow at a CAGR of 10.53% from 2016 to 2020. These stocks research reports can be downloaded now by simply registering for free at:


On Tuesday, shares in Jersey City, New Jersey headquartered SCYNEXIS Inc. recorded a trading volume of 576,451 shares. The stock ended the day at $4.49, which was a drop of 1.32%. The Company's shares have surged 62.68% in the last one month and 99.56% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 58.64% and 20.12%, respectively. Furthermore, shares of SCYNEXIS, which develops and commercializes novel anti-infectives to address unmet therapeutic needs, have a Relative Strength Index (RSI) of 75.30.

On August 24th, 2016, SCYNEXIS announced that the US FDA has granted orphan drug designation to the company's novel triterpenoid broad-spectrum antifungal agent, SCY-078, for the treatment of invasive Aspergillus infections. The orphan drug designation of SCY-078 provides seven years of market exclusivity in the U.S. following FDA approval of an NDA for the orphan designated indication.

On October 3rd, 2016, research firm Brean Capital resumed its 'Buy' rating on the Company's stock. Your complete research report on SCYX can be retrieved for free at:

Supernus Pharma  

Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s stock finished yesterday's session 0.97% lower at $23.52 with a total trading volume of 493,989 shares. The Company's shares have gained 7.06% in the last one month, 8.99% over the previous three months, and 75.00% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.84% and 32.78%, respectively. Furthermore, shares of Supernus Pharmaceuticals, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 44.98. SUPN free report is just a click away at:


At the closing bell on Tuesday, shares in Salt Lake City, Utah headquartered Lipocine Inc. saw a decline of 6.39%, ending the day at $4.25. The stock recorded a trading volume of 158,117 shares. The Company's shares have advanced 22.13% in the last one month and 32.81% over the previous three months. The stock is trading 13.28% above its 50-day moving average. Moreover, shares of Lipocine, which develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health, have an RSI of 57.78.

On September 26th, 2016, Lipocine reported positive top-line results from a Phase 2b clinical study of LPCN 1111, a novel oral testosterone replacement therapy product candidate. The primary objectives of the study were to determine the Phase 3 dose of LPCN 1111 along with the safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses in hypogonadal males. Results of the Phase 2b study suggest that the primary objectives were met. Sign up for your complimentary research report on LPCN at:

Carbylan Therapeutics  

Palo Alto, California headquartered Carbylan Therapeutics Inc.'s stock ended the day 3.84% higher at $0.47 with a total trading volume of 230,894 shares. Shares of the Company, which focuses on the development and commercialization of novel and proprietary combination therapies, are trading 7.67% below their 50-day moving average. The stock has an RSI of 47.27.

As per notes filed with the SEC on September 30th, 2016, the company noted that on September 26th, 2016, a purported stockholder class action complaint was filed in the Superior Court of the State of California in and for the County of Alameda against Carbylan Therapeutics, Inc. the members of the board of directors of Carbylan, as well as against KalVista Pharmaceuticals Ltd., Wedbush Securities Inc. and certain unknown employees of Wedbush. The complaint alleges that the members of Carbylan's board of directors and/or Carbylan breached their fiduciary duties of care, good faith, loyalty and/or disclosure in connection with the Share Purchase Agreement, dated as of June 15th, 2016, by and among Carbylan, KalVista, and the shareholders of KalVista, and that KalVista and Wedbush aided and abetted such breaches of fiduciary duties. The complaint seeks to enjoin and/or rescind any transaction with KalVista as well as certain other equitable relief, unspecified damages and attorneys' fees and costs. Carbylan believes this lawsuit is without merit and intends to vigorously defend against it.

Register for free on and download the latest research report on CBYL at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA